Psoriasis and Beyond: The global psoriatic disease study

Psoriasis is a common chronic inflammatory disease that affects at least 60 million people worldwide1. People are most familiar with the patches of inflamed skin that are associated with the disease, but the impact of living with psoriasis goes far beyond the skin.

Psoriasis itself, its joint symptoms, and other illnesses that can be associated with it (comorbidities) are collectively referred to as psoriatic disease2.

The Psoriasis and Beyond study assessed people’s understanding of psoriatic disease and takes a closer look at its broader impact, including connected comorbidities, how the disease affects a person’s quality of life, and their conversations with their doctor.

Dive into the study findings to discover the many layers of psoriatic disease and start the conversation with your doctor today.

Key findings

Asset 3 1280x920 1 100

Beyond the skin

The vast majority of people living with psoriatic disease are not aware of its systemic nature and associated comorbidities.

Over 80% of participants are unaware of the increased risk of cardiovascular disease and diabetes associated with psoriatic disease3.

*According to The Psoriasis Epidemiology Screening Tool (PEST)

Asset 2 1280x920 100

Quality of life

The effect of psoriatic disease on a person’s quality of life, their relationships and mental health can be profound.

Even participants with mild disease (60%) reported a moderate to extremely large effect on their quality of life3.

Asset 3 1280x920 100

Satisfaction with treatment

Overall, 59% of participants feel they have no opportunity to talk with their doctor about what they hoped to achieve from their treatment.

Some participants living with psoriatic disease feel their skin and joint symptoms, as well as their quality of life, are not improving adequately on their current treatment3.

Collaboration

Psoriasis and Beyond is a joint research initiative between IFPA, 16 national psoriasis organizations and Novartis Pharma AG. The study is overseen by a Steering Committee of patient advocates, dermatologists and rheumatologists.

Novartis Pharma AG sponsored both this study and the writing of the accompanying Summary of Research Findings.


Oct 2021 | 173316


References

1. Global Psoriasis Atlas. Available from: https://www.globalpsoriasisatlas.org/en/ Last accessed: October 2021.
2. Ritchlin C. Psoriatic disease--from skin to bone. Nat Clin Pract Rheumatol. 2007 Dec;3(12):698-706.
3. Armstrong A, Bohannan B, Mburu S, et al. A Closer Look at Patients' Perspectives on Psoriatic Disease Burden: Results from the Global Survey Psoriasis and Beyond. Abstract at 2021 Fall Clinical Dermatology. Abstract FC21.